Premium Company Profile - Endo Pharmaceuticals - New Research Report on Companies and Markets Company-Profile/Premium-Comp ..Introduction Endo Pharmaceuticals main focus is to develop and market prescription drugs for pain management.
The companys marketed product, Lidoderm, indicated for the relief of pain associated with post...
Transdel Pharmaceuticals to Present at 2008 BIO International Convention /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically administered medications, today announced that Dr.
Juliet Singh,...
Transdel Pharmaceuticals to Present at 2008 BIO International Convention LA JOLLA, Calif., June 17 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc.(OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically administered...
Transdel Pharmaceuticals to Present at 2008 BIO International Convention LA JOLLA, Calif., June 17 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc.(OTC Bulletin Board: TDLP - News), a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically...
Transdel Pharmaceuticals to Present at 2008 BIO International Convention LA JOLLA, Calif., June 17 CA-Transdel-2008-BIO LA JOLLA, Calif., June 17 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc.(OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on the development and...
Transdel Pharmaceuticals to Present at 2008 BIO International Convention LA JOLLA, Calif., June 17 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc.(OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically administered...
Transdel Pharmaceuticals to Present at 2008 BIO International Convention LA JOLLA, Calif., June 17 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc.(BULLETIN BOARD: TDLP), a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically administered...
Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain Cato Research Signed as Strategic Partner for the Phase 3 Program LA JOLLA, Calif., June 16 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company developing non-invasive, topically administered...
Evaluating OTC painkiller options MCT NEWS Which over-the-counter pain-reliever is safest: acetaminophen, ibuprofen, naproxen or ketoprofen? All these drugs are considered safe for short-term use (up to 10 days) in most people?
That's why they got the OTC nod.
Choosing OTC painkillers Q: Which over-the-counter pain-reliever is safest: acetaminophen, ibuprofen, naproxen or ketoprofen? A: All these drugs are considered safe for short-term use (up to 10 days) in most people?
That's why they got the OTC nod.
SALAs Offer No Edge Over Other NSAIDs in Reducing Alzheimer's Risk Contrary to recent reports, selective A-42lowering agents (SALAs) a subgroup of nonsteroidal anti-inflammatory drugs (NSAIDs) that includes ibuprofen offer no greater protection against Alzheimer's disease (AD) than other NSAIDs.A pooled...
Softgel Drug Delivery Systems Softgel formulation characteristics consist of water or oil soluble fill solution, or suspension of drug covered by a layer of gelatine (made of gelatine, plasticiser, modifier, water, colour, antioxidant or flavour).The outer layer can...
Drug-eluting stent having collagen drug carrier chemically treated with genipin Title: United States Patent: 7,351,421 Inventors: Sung; Hsing-Wen (Hsinchu, TW), Chen; Mei-Chin (Taishan Shiang, TW), Tu; Peter Y (Irvine, CA), Tu; Hosheng (Newport Beach, CA) Appl.No.: 10/811,413 Filed: March 26, 2004 A method for...
Alpharma Announces Updated Financial Outlook for 2008 - Alpharma Inc.(NYSE The Company expects 2008 revenue growth from its continuing operations to be in the range of 30% to 35% over the $535 million in revenues in 2007.
Earnings per share from continuing operations are projected in the...
